Investor Presentation

October 2026



MIMEDX

Disclaimer & Cautionary Statements

This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-looking statements include statements regarding:

- Growing expansion outside of the U.S.;
- Our growth expectations in 2026 and beyond, including our growth in surgery, increased funding in targeted research and expanded product portfolio;
- Expected results of research and development, including that our efforts will innovate and diversify our product portfolio;
- Placental-derived products and their potential clinical benefits;
- EPIEFFECT® and CHORIOFIX™ randomized controlled trial enrollment;
- Expectations regarding the reimbursement environment for the Company's products, including Medicare Spending;
- Expectations regarding HELIOGEN®, AMNIOFIX®, AMNIOEFFECT®, as well as Hydrelix, NovaForm®, and G4Derm® Plus driving Surgical growth;
- Our expectations that we will continue to advocate for Medicare spending reform;
- Exposure to tariffs and the anticipation that they will not impact the Company's results;
- Our 2026 full-year net sales outlook, our expectation that fourth-quarter 2026 Adjusted EBITDA will increase sequentially, our long-term net sales growth and Adjusted EBITDA margin targets, our long-term non-GAAP effective tax rate, and top-line growth post reform in Medicare spending;
- Our ability to manage Private Office and Wound Care Center/Hospital Outpatient dynamics, including adjusting our strategy to remain competitive;
- The proposed acquisition of Sanara MedTech Inc. ("Sanara"), including the expected timing and completion of the transaction; the FTC's review, including the Second Request, and the expiration or termination of the HSR waiting period; the Hayfin debt financing commitment and related ticking fee; the expected revenue, cost synergies, Adjusted EBITDA margin, free cash flow and net leverage of the combined company; and integration planning; and
- The Company's long-term strategy and goals for value creation, the status of its pipeline products, expectations for future products, and expectations for future growth and profitability

Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include:

- Future sales are uncertain and are affected by competition, access to customers, patient access to hospitals and healthcare providers, the reimbursement environment and many other factors;
- The future market for the Company's products can depend on regulatory approval of such products, which might not occur at all or when expected, and is based in part on assumptions regarding the number of patients who elect less acute and more acute treatment than the Company's products, market acceptance of the Company's products, and adequate reimbursement for such therapies;
- The process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all, and the ability to obtain the rights to market additional, suitable products depends on negotiations with third parties which may not be forthcoming;
- Risks relating to the proposed Sanara acquisition, its financing and our existing credit facility, including but not limited to the timing of closing, the outcome and timing of the FTC review and Second Request process, the risk that financing under the Hayfin commitment is not available when needed, the impact of ticking fees or termination fees, integration risks, the possibility that expected synergies are not realized as expected, and the possibility that the transaction is delayed or not completed.

The Company describes additional risks and uncertainties in the Risk Factors section of its most recent annual report and quarterly reports filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this presentation and the Company assumes no obligation to update any forward-looking statement.

Disclaimer

No Offer or Solicitation

This presentation does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy any securities or a solicitation of any vote or approval with respect to the Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Important Information and Where to Find It

In connection with the proposed transaction, MiMedx filed with the SEC a registration statement on Form S-4 that includes a proxy statement of Sanara and that also constitutes a prospectus of MiMedx. Each of MiMedx and Sanara may also file other relevant documents with the SEC regarding the proposed transaction. This communication is not a substitute for the prospectus or registration statement or any other document that MiMedx or Sanara may file with the SEC. The final prospectus has been mailed to stockholders of Sanara. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT, PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the registration statement and prospectus) and other documents containing important information about MiMedx, Sanara and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by MiMedx will be available free of charge on MiMedx's website at https://investors.mimedx.com/.

Participants in the Solicitation

Sanara MedTech, the Company and their respective directors and certain of their executive officers and other members of management and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from Sanara's stockholders in connection with the Transactions. Information regarding the executive officers and directors of the Company is included in its Proxy Statement filed with the SEC on April 29, 2026. Information regarding the executive officers and directors of Sanara MedTech is included in its Proxy Statement filed with the SEC on April 17, 2026. Additional information regarding the persons who may be deemed participants and their direct and indirect interests, by security holdings or otherwise, will be set forth in the Registration Statement and other materials when they are filed with the SEC in connection with the Transactions. Free copies of these documents may be obtained as described in the paragraphs above.

Non-GAAP Financial Measures

This presentation includes non-GAAP financial measures, including Adjusted EBITDA and related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin, Adjusted Net Income, Adjusted SG&A, Adjusted R&D and Adjusted Earnings Per Share. These measures are not prepared in accordance with GAAP, should be considered in addition to, and not as a substitute for the most directly comparable GAAP measures, and may not be comparable to similarly titled measures of other companies. Reconciliations of historical non-GAAP measures to the most directly comparable GAAP measures are included in the Appendix and in our earnings release dated October 28, 2026.

We have not provided a reconciliation of forward-looking Adjusted EBITDA (including expected fourth-quarter 2026 Adjusted EBITDA), long-term and combined-company Adjusted EBITDA margin targets, or forward-looking net leverage to the most directly comparable GAAP measures because we are unable to do so without unreasonable efforts. We cannot predict with reasonable certainty the timing or amount of items excluded from these measures, such as acquisition and transaction-related costs relating to the proposed Sanara acquisition, strategic legal and regulatory expenses, reorganization expenses, share-based compensation and income tax effects, which could be material to our GAAP results.

MIMEDX – A Pioneer & Leader Delivering Healing Solutions in Healthcare

HELPING



Expanding Surgical footprint

as we demonstrate positive clinical and economic outcomes using our Surgical products

HUMANS



An industry pioneer

in Advanced Wound Care with a product offering backed by a compendium of scientific and clinical evidence

HEAL



Strong financial discipline

as focused capital deployment and expense management supports continued growth, profitability & cash flow

At MIMEDX, our vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.


MIMEDX

Investment Rationale



Addressing large, growing Surgical markets

and continuing a legacy of leadership in Wound



Key competitive advantages

with innovative products, extensive IP and broad sales reach



Planned Acquisition of Sanara MedTech

accelerates Surgical growth



Experienced leadership team

driving company strategy



Strong balance sheet

and cash flow generation

Proposed Acquisition of
Sanara MedTech

MIMEDX

Sanara Meaningfully Accelerates Efforts to Expand Surgical Footprint

Key Transaction Highlights



100% Surgical / OR Business

+$4B

Unlocks Sizable ***Incremental*** TAMs[1]



Transforms Surgical Footprint & Financial Profile



Leading Particulate



Expanding Product Portfolio



Robust R&D Pipeline

1 – Calculated using Definitive Healthcare Database, LSI Procedural Data, published orthopedic market research data and related journals, surgeon validation, and Sanara estimates

About Sanara MedTech

Pure-play surgical solutions business focused on the operating room setting, with innovative technologies, strong IP, a proven and scalable commercial engine and a compelling margin profile.

Sanara MedTech

Progressive Portfolio Strategy Across the Surgical Workflow

BIASURGE® Advanced Surgical Solution


OsStic™ BioAdhesive ADVANCED BONE FIXATION

Cellerate® RX Surgical HYDROLYZED COLLAGEN

PREPARE



PROMOTE



PROTECT



Select Financial Highlights (2025)[1]

$103MM 2025 Net Revenue	**19%** Y/Y Growth	**51%** 7-Year CAGR	
93% Gross Margin	**$7MM** Operating Income	**$17MM** Adjusted EBITDA	**$17MM** Cash

40+ Field Sales Team

450+ Contracted Distributors

1,450+ Active Facilities

4,000+ Contracted Facilities

MIMEDX

1 – Historical financial information based on Sanara's public filings

Strong Business Alignment Drives Compelling Deal Rationale

- **Expands Product Offering with Differentiated, Innovative Technologies**
- **Adds Significant Commercial Scale Through Distribution Network**
- **Immediately Accretive to Revenue Growth & Profitability**
- **Strong Cultural Fit; Talent Profile Adds Deep Industry Expertise**



BIASURGE®
No-Rinse Surgical Irrigation Solution



OsStic™
Synthetic Injectable Structural Bio-Adhesive



CellerateRX® Surgical
Leading Collagen Particulate

MIMEDX

Transaction Details

MIMEDX + Sanara MedTech

Consideration

- Acquiring Sanara for $35 per share, representing a 46% premium to Sanara's 30-day volume weighted average share price as of July 28, 2026
- Purchase price comprised of:
  - $33 per share in cash and,
  - 0.4735 shares of MIMEDX common stock for each share of Sanara common stock they own, which represents a value of $2.00 per share, calculated based on the average closing price of MIMEDX common stock of $4.22 for the last five consecutive trading days through and including July 28, 2026
- Total Enterprise Value: Approximately $350 million

Run-Rate Cost Synergies & Combined Financial Profile

- In the first full year post-close, anticipating:
  - Total revenue close to $400 million on a combined basis
  - Over $20 million in annualized, run-rate cost synergies to be realized in 2027 in connection with the acquisition
  - Adj. EBITDA margin to be above 20%

Financing

- MIMEDX has obtained fully committed financing through Hayfin Capital Management, LLP
- Acquisition to be funded with a combination of cash on hand and a new $300 million Senior Secured Term Loan
- Terms:
  - 6 years
  - SOFR + 6.25%
- MIMEDX expects to issue 4.4 million shares for the stock consideration portion of the transaction

Approvals

- Each company's board of directors have unanimously approved the transaction
- Obtained Sanara shareholder approval on September 30
- FTC clearance remains last major hurdle to closing

About MIMEDX

Surgical Markets Offer a Large, Expanding Opportunity Outside of Wound Care

LARGE SURGICAL MARKET

~92 million

Surgical procedures performed in the US each year[1]

~23 million

General surgery procedures performed in the US each year[1]

+$4B

Incremental addressable market unlocked by the Sanara acquisition[2]

GROWING MIMEDX PRESENCE

15%

Surgical sales growth based upon LTM Q3:26 vs. LTM Q3:25

8 studies

Underway across surgical disciplines, with 5 published since May 2025

Expanding Offering

Non-placental derived products, like HELIOGEN® and G4Derm® Plus augmenting Surgical growth

Surgical Complications Burden Providers and Payors, Creating Demand for Products That Improve Outcomes

MIMEDX

1 - Life Science Intelligence, U.S. Surgical Procedure Volumes Database: inpatient and outpatient procedures, 2024.
2 - Calculated using Definitive Healthcare Database, LSI Procedural Data, published orthopedic market research data and related journals, surgeon validation, and Sanara estimates.

Targeting Surgical Applications That Reduce Health & Economic Burdens

Compelling Data Supporting Use of MIMEDX Products in Colorectal Anastomosis Procedures

THE PROBLEM

Anastomotic leaks are a **serious postoperative complication** of intestinal surgeries, with significant health and economic consequences that burden providers, payors and patients

LEAK COMPLICATIONS INCLUDE[1]


Increased Morbidity & Mortality	**Increased Readmission Rates**
Increased Reoperation Rate	**Extended Length of Stay**
Increased Hospitalization Costs	**Reduced Quality of Life**

~$28M

economic burden of anastomotic leaks per 1,000 patients[2], a multibillion cost to the healthcare system


THE SOLUTION

Recent studies demonstrate AMNIOFIX recipients experienced **significant reductions in leak rates and hospital readmissions**



Anastomotic leak rate


48% lower vs NSQIP | 63% lower vs PHD



Leaks/n: 11/566 vs 520/13,684 (p=0.0002*); 13/566 vs 6,174/99,879 (p=0.0229*)

30-day hospital readmissions

40% lower vs NSQIP | 49% lower vs PHD



Readmissions/n: 32/566 vs 1,290/13,684 (p=0.0031*); 32/566 vs 11,079/99,879 (p=0.0001*). *Two-tailed Chi-square with Yates correction

1) Rennie O, Sharma M, Helwa N. Colorectal anastomotic leakage: a narrative review of definitions, grading systems, and consequences of leaks. *Front Surg*. 2024;11:1371567. Published 2024 May 2.
2) Hammond J, Lim S, Wan Y, Gao X, Patkar A. The burden of gastrointestinal anastomotic leaks: an evaluation of clinical and economic outcomes. J Gastrointest Surg. 2014;18(6):1176-1185.

MIMEDX

Additional Surgical Studies Underway Highlight Product Versatility

ENROLLMENT / ANALYSIS → **MANUSCRIPTS / REVIEW** → **PUBLISHED**



AMNIOFIX

Liver Transplant

Interim analysis upcoming



AMNIOFIX

Esophageal Reconstruction

Under review

Plastic & Reconstructive Surgery



AMNIOEFFECT & AXIOFILL

High-Risk Vascular

Published April 2026

Vascular



AMNIOFIX

Colorectal Anostomosis

European Surgical Research, Mar 2026

Frontiers in Surgery, Sept 2026



AMNIOFIX

Breast Reduction

Study analysis underway



AMNIOFIX

Endoscopic Spine Lumbar Discectomy

Manuscript in development



AMNIOFIX

ACL Repair

E-Published December 2025

Journal of Orthopaedic Reports



AMNIOFIX

Prostatectomy

Published October 2026

Journal of Robotic Surgery

Generating Clinical Data in Numerous Surgical Disciplines Incorporating Use of MIMEDX Products

MIMEDX

Addressing a Large and Unmet Need for Wound Healing Solutions

FAVORABLE DEMOGRAPHIC TRENDS

>10 million

People in the US suffering from chronic and hard-to-heal wounds[1]

1 in 6

Medicare beneficiaries affected by these wounds[1]

~$150 billion

Global expenditure on wound care[1]

INCREASING CLINICAL EVIDENCE

Up to 85%

Of amputations are avoidable using a wound care approach that incorporates innovative treatments[2]

EPIFIX®

Recipients experienced reductions in major amputations and hospital utilization[2]

98.5% higher

Probability of wound closure compared to standard-of-care in latest literature[3]

15+ YEARS

EPIFIX®



#1 Most studied human placental allograft

MIMEDX

Opportunities to Use Innovative Allografts Driven by Combination of Macro Factors and Increased Physician / Surgeon Awareness

MIMEDX

1 - Sen CK, et al. Human Wound and Its Burden: Updated 2025 Compendium of Estimates. Adv Wound Care (New Rochelle). 2025; doi: 10.1177/21621918251359554
2 - Tettelbach WH, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022 Feb 1;31(Sup2):S10-S31.
3 - Serena, T. E., et al. Evaluation of lyophilized human amnion/chorion membrane (LHACM) in the management of nonhealing diabetic foot ulcers: An interim analysis of the CAMPAIGN trial. International Journal of Tissue Repair. 2025. https://doi.org/10.63676/tk3kw419

The Most Comprehensive End-To-End Product Ecosystem

Leading the field with science, clinical efficacy and a customer and patient-centric go-to-market mindset

1 Clinical evidence

The most studied portfolio of placental products with a growing compendium of published **scientific**, **clinical** and **health outcome** data

2 Tissue supply

placenta donation PROGRAM

Large, national placental donation network and **proprietary tissue processing**.

3 Product innovation



New product innovations leading to untapped opportunities for growth, including an **increasing footprint in the Surgical market**.

4 Customer focus



A key partner to healthcare professionals with industry leading support services and **customer-focused approach**.

MIMEDX

The Most Comprehensive End-To-End Product Ecosystem

Unmatched peer-reviewed published evidence supporting our product portfolio

1 Clinical evidence | 2 Tissue supply | 3 Product innovation | 4 Customer focus




Peer-reviewed research

Publications in *Nature Scientific Reports* and the *Journal of Inflammation* are Recent Examples of Top Tier **Peer Reviewed Scientific Research Using MIMEDX Products**

EPIEFFECT®

Randomized controlled trial

Interim RCT Results **Demonstrate Clinical Benefit** Associated with Use of EPIEFFECT Compared to Standard of Care



Payor & GPO access

Broadest commercial payor coverage, GPO relationships and increasing hospital value analysis committee wins result in wide product availability

MIMEDX

The Most Comprehensive End-To-End Product Ecosystem

National footprint with labor and delivery centers to obtain placental tissue

1 Clinical evidence | **2 Tissue supply** | 3 Product innovation | 4 Customer focus

National network of birthing center partners



Expectant Mothers Introduced to Donation Program

Consent for Donation Obtained

Delivery of Healthy Baby via Caesarean Section

Donated Placental Tissues Recovered

Tissues Transported to MIMEDX

Donor Tissue Tested & Prepared for Manufacturing

placenta donation PROGRAM

Large, national placental donation network and **proprietary tissue processing.**

MIMEDX

The Most Comprehensive End-To-End Product Ecosystem

Leveraging robust IP portfolio, knowhow and expertise to drive continued innovations for Wound & Surgical markets

1 Clinical evidence | 2 Tissue supply | **3 Product innovation** | 4 Customer focus

New product innovations leading to untapped opportunities for growth, including an **increasing footprint in the Surgical market**.

Purion®

Proprietary Processing Backed by Broad Portfolio of Intellectual Property

- Robust IP Estate with 200+ Patents
- Significant Opportunity for Continued Scale
- Shelf-Stable, Packaged Product Available to Ship



Ample Placental Supply and Manufacturing Capabilities to Support Continued Growth and Industry Demand


MIMEDX

The Most Comprehensive End-To-End Product Ecosystem

MIMEDX Connect offers a full suite of practice management tools in a single online portal

1 Clinical evidence | 2 Tissue supply | 3 Product innovation | **4 Customer focus**

A key partner to healthcare professionals with industry leading support services and **customer-focused approach.**




Helps customers simplify workflows, maximize efficiency and increase lifetime value of each customer

Features include

- Order management
- Insurance verification status
- Bill pay

Strategic Priorities Focus on Product Innovation & Market Opportunities



01

Continuing to innovate and diversify our portfolio across product platforms

Numerous opportunities and areas for expansion



02

Driving higher growth in surgical markets

Shifting revenue mix to more stable and opportunistic market

Q3:26 Operating & Financial Highlights

Net Sales

$62MM

Surgical Net Sales

+9%

vs. Q3:25

Mid-teens % volume growth

Wound Care Centers



Upper single-digit % volume growth vs. Q2:26

GAAP Gross Margin

80%

+11 percentage points vs. Q2:26

Adj. EBITDA[1]

$2MM

+$10MM vs. Q2:26

GAAP Net Loss

($9MM)

+$6MM vs. Q2:26

Business Highlights

AXIOFILL® ECM PARTICULATE

Favorable court ruling in FDA litigation; remands regulatory classification decision back to FDA

Patent Settlement & License Agreement

Announced settlement and license agreement with a competitor Wound Care company, resolving a patent infringement allegations involving MIMEDX's IP portfolio

MIMEDX to receive a total of **$25 million** in five equal installments of $5 million annually

MIMEDX

1) Adjusted EBITDA is a non-GAAP financial measure. See the Appendix for a reconciliation to the nearest GAAP measure.

Experienced, Skillful Leadership Team Executing Strategy

Management Team with Track Record of Success in MedTech



Joe Capper
Chief Executive Officer



Doug Rice
Chief Financial Officer



Butch Hulse
Chief Administrative Officer & General Counsel



Kim Moller
Chief Commercial Officer



John Harper, Ph.D.
Chief Scientific Officer & SVP, R&D



Tracy Chastain
Chief Human Resources Officer



David McGill
VP, Manufacturing & Engineering



Matt Notarianni
Head of IR

Prior Roles Include:

3M, Acelity, Bayer, Orthofix, McKesson, SCP Health, KCI, CCS, Cerus, Concentra, Immucor, Dykema, Asensus Surgical, Baird, McAfee, HOMEdiagnostics, Vision Source Signature Eye Care, BioTelemetry, Facet Medical Technologies, Deka


MIMEDX

Investment Rationale



Addressing large & expanding Surgical markets

and continuing a legacy of leadership in Wound



Key competitive advantages

with innovative products, extensive IP and broad sales reach



Planned Acquisition of Sanara MedTech

accelerates Surgical growth



Experienced leadership team

driving company strategy



Strong balance sheet

and cash flow generation

THANK YOU

MIMEDX
1775 West Oak Commons Ct.
Marietta, GA 30062
888.543.1917 | 770.651.9100

MIMEDX

Appendix

Adjusted EBITDA - QTD

Amounts (in millions) for the three months ended September 30,	2026	2025
Net income - GAAP	$ (8.7)	$ 16.7
Strategic legal and regulatory expenses	5.7	2.5
Acquisition and other transaction-related costs	3.3	0.2
Stock-based compensation expense	3.2	4.9
Amortization of intangible assets	1.1	4.7
Depreciation expense	0.4	0.6
Strategic software implementation costs	0.3	—
Interest (income) expense, net	(0.8)	(0.8)
Income tax provision	(2.4)	6.1
Adjusted EBITDA	$ 2.1	$ 35.0
Adjusted EBITDA margin	*3.3 %*	*30.7 %*

Adjusted EBITDA - YTD

Amounts (in millions) for the nine months ended September 30,	2026	2025
Net income - GAAP	$ (34.4)	$ 33.4
Strategic legal and regulatory expenses	14.1	6.7
Reorganization expenses	3.8	0.8
Acquisition and other transaction-related costs	3.4	0.8
Amortization of intangible assets	3.3	10.0
Stock-based compensation expense	2.4	13.9
Depreciation expense	1.3	1.7
Strategic software implementation costs	0.6	—
Interest expense, net	(2.4)	(2.0)
Income tax provision	(9.8)	11.1
Adjusted EBITDA	$ (17.6)	$ 76.3
Adjusted EBITDA margin	*(9.5)%*	*25.4 %*

MIMEDX

Adjusted Net Income and Adjusted EPS - QTD

Amounts (in millions) for the three months ended September 30,	2026	2025
Net income - GAAP	$ (8.7)	$ 16.7
Strategic legal & regulatory expenses	5.7	2.5
Acquisition and other transaction-related costs	3.3	0.2
Amortization of acquired intangible assets	0.8	4.6
Strategic software implementation costs	0.3	—
Adjustment for income taxes	(2.1)	(1.4)
Adjusted net income	$ (0.7)	$ 22.6
Weighted average common shares outstanding - adjusted (in millions)	145.9	149.7
Adjusted EPS	$ (0.01)	$ 0.15

MIMEDX

Adjusted Net Income and Adjusted EPS - YTD

Amounts (in millions) for the nine months ended September 30,	2026	2025
Net income - GAAP	$ (34.4)	$ 33.4
Strategic legal & regulatory expenses	14.1	6.7
Reorganization expenses	3.8	0.8
Acquisition and other transaction-related costs	3.4	0.8
Amortization of acquired intangible assets	2.5	9.7
Strategic software implementation costs	0.6	—
Adjustment for income taxes	(4.9)	(4.5)
Adjusted net income	$ (14.8)	$ 46.8
Weighted average common shares outstanding - adjusted (in millions)	147.4	149.6
Adjusted EPS	$ (0.10)	$ 0.31

MIMEDX